Immunocore’s flotation in the US has raised $258 million.   The pricing of its initial public offering on the Nasdaq in New York, managed by investment banks Goldman Sachs, JP Morgan and Jefferies, is $158m higher than it expected in January.  The Oxford-based company, which delivers biological therapies that have the potential to transform the lives of people with serious diseases including cancer, has also raised $15m in … Continue reading UK BioTech Immunocore raises $273m as it launches upsized US flotation